Navigation Links
ViroPharma Improves Financial Position Through Repurchase of $45 Million Principal Amount of Senior Convertible Notes
Date:3/24/2009

atements in this press release contain forward-looking statements that involve a number of risks and uncertainties. Forward-looking statements provide our current expectations or forecasts of future events and include our estimates of the tax and accounting treatment of the repurchase of our senior convertible notes or purchase shares of our common stock or convertible notes. Factors that could affect our financial position generally, and therefore impact the timing and magnitude of any possible future repurchase of notes or common stock, include among other things: the timeframe in which the FDA make a decision regarding either our citizen petition for Vancocin or the approval of generic versions of Vancocin; our ability to execute a successful launch of Cinryze; our ability to conduct future studies with maribavir; and the timing and potential outcomes of the review of our regulatory submission related to an acute treatment indication for Cinryze; the timing and nature of potential business development activities related to our efforts to expand our current portfolio through in-licensing or other means of acquiring products in clinical development or marketed products; and approval of products which are currently marketed for other indications by other companies or new pharmaceuticals and technological advances to treat the conditions addressed by Vancocin or Cinryze. Currently our market capitalization is less than our book value. As a result, we may be required to take a significant non-cash goodwill impairment charge and may be required to write off goodwill or other intangible assets in the future. If we are required to write off goodwill or other intangible assets, our financial position or results of operations could be adversely affected. These factors, and other factors, including, but not limited to those described in the our annual report on Form 10-K filed with the Securities and Exchange Commission in February 2009, could cause future results to diffe
'/>"/>
SOURCE ViroPharma Incorporated
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. ViroPharma Incorporated Reports Fourth Quarter and Full Year 2008 Financial Results
2. ViroPharma to Present at Three November Healthcare Conferences
3. ViroPharma Enhances Leadership to Support Global Growth and Expanding Business
4. ViroPharma to Release 2008 Third Quarter Financial Results on October 29, 2008
5. ViroPharma to Present at Three October Healthcare Conferences
6. ViroPharma to Present at Three September Healthcare Conferences
7. ViroPharma To Acquire Lev Pharmaceuticals
8. ViroPharma Provides Update on Upcoming FDA Advisory Committee Meeting to Discuss Bioequivalence of Locally Acting Gastrointestinal Drugs
9. Viropharma Comments On Upcoming FDA Advisory Committee Meeting
10. ViroPharma to Present at Two Upcoming Healthcare Conferences
11. ViroPharma to Present at the Seventh Annual JMP Securities Research Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/10/2014)... (PRWEB) July 10, 2014 Terascala, the ... announced that Alan Swahn, a former vice president of ... team as vice president of marketing. Terascala’s software when ... and NetApp create the highest performance and most reliable ... appointed to guide Terascala’s channel expansion and broaden its ...
(Date:7/10/2014)... Robert Harman, DVM, Founder and CEO of Vet-Stem, Inc., ... the relaunch of his highly informative blog, now named Stem ... What are Stem Cells ?” Dr. Harman’s purpose for ... the basics of stem cell therapy so that pet owners ... treatment when considering regenerative medicine. , A veterinarian by trade, ...
(Date:7/10/2014)... EvoDerma ’s NOOME Anti-Aging Motion has ... now comes with a second treatment cup to help prevent ... new cup is thinner on the edges for a softer ... thin and uneven surfaces on the face, neck and décolleté. ... treatment on areas such as the cheeks and neck, or ...
(Date:7/10/2014)... 10, 2014  Franciscan St. Anthony Health-Crown ... for respiratory monitoring outside the operating room, ... in embracing state-of-the-art patient safety technology. ... breathing and can alert medical caregivers when ... amount of carbon dioxide the patient is ...
Breaking Biology Technology:Terascala Expands Executive Team 2Terascala Expands Executive Team 3Robert Harman, DVM Talks About What Stem Cells are in His Latest Blog Series for Vet-Stem, Inc. 2Robert Harman, DVM Talks About What Stem Cells are in His Latest Blog Series for Vet-Stem, Inc. 3Introducing a New Bonus Treatment Cup for EvoDerma’s NOOME Anti-Aging Motion 2Franciscan St. Anthony Health-Crown Point Underscores Patient Safety Commitment Through Expanded Use of Capnography 2
... June 6, 2011 At the White House today, ... the seven U.S. recipients of the 2010 Kavli Prizes ... three fields for which the Prizes are awarded -- ... http://photos.prnewswire.com/prnh/20110606/DC14848 ) Joined by the President,s science ...
... Inc., the recognized leader in microbiology, infectious disease ... transplant and biomedical sciences communities, today announced that ... of Strategic Development following two years with the ... Inc. client base significantly. In Ronholdt,s ...
... Biotech announced the sale of its leading ... probiotic dietary supplements to Schiff Nutrition International, Inc. ... receive royalties on Schiff products containing GanedenBC30 ™. ... Ganeden,s probiotic technology, GanedenBC30™, in the over-the-counter (OTC) and ...
Cached Biology Technology:President Obama Meets U.S. Laureates of 2010 Kavli Prizes 2President Obama Meets U.S. Laureates of 2010 Kavli Prizes 3LABS, Inc. Promotes Chad Ronholdt to VP of Strategic Development 2Ganeden Biotech Completes $40 Million Sale of Sustenex® and Digestive Advantage® Probiotic Brands 2Ganeden Biotech Completes $40 Million Sale of Sustenex® and Digestive Advantage® Probiotic Brands 3
(Date:7/10/2014)... New York , July 7, 2014 ... by Transparency Market Research "Electronic Access Control Systems Market ... 2014 - 2019," the global Electronic Access Control systems ... and is expected to grow at a CAGR of ... value of USD 31,187.8 million in 2019. ...
(Date:7/10/2014)... 2014  Acuity Market Intelligence today released forecasts from "The ... that the global market for National Electronic ID (eID) programs ... During this time, the number of National eID cards in ... Asia , with its vast population, will dominate ... issued, while Europe trails a distant ...
(Date:7/10/2014)... mainly tropical flowering plant family Melastomataceae (Meadow Beauty Family). Most ... bees for their pollination. Only about 100 are known to ... Axinaea appear in clusters of few to more ... are pink, yellow, orange or red. The stamens (male reproductive ... bulbous appendages. The pollination mechanism of Axinaea had ...
Breaking Biology News(10 mins):Electronic Access Control Systems Market is Expected to Reach USD 31.2 Billion Globally in 2019: Transparency Market Research 2Electronic Access Control Systems Market is Expected to Reach USD 31.2 Billion Globally in 2019: Transparency Market Research 3Electronic Access Control Systems Market is Expected to Reach USD 31.2 Billion Globally in 2019: Transparency Market Research 4Electronic Access Control Systems Market is Expected to Reach USD 31.2 Billion Globally in 2019: Transparency Market Research 5National Electronic ID Programs Generate $54 Billion Between 2013 and 2018 with 3.5 Billion National eID Card Holders Worldwide 2Novel type of bird pollination mechanism discovered in South America 2
... DC - New research suggests that monoclonal antibody therapy of ... it is today, says a researcher at Georgetown University Medical ... of the Lancet . "We believe that antibody ... Louis Weiner, MD, director of the cancer center at GUMC ...
... rigorous environmental cleaning intervention can reduce the transmission ... other multidrug-resistant organisms in hospital intensive care units ... at the annual meeting of the Society for ... that following an enhanced cleaning protocol reduced the ...
... of a new study into plant sex and discovered ... The study takes to a new level understanding of ... Professor David Twell and colleagues in the Department of ... a gene that has a critical role in allowing precursor ...
Cached Biology News:Lombardi research: Monoclonal antibodies primed to become potent immune weapons against cancer 2Lombardi research: Monoclonal antibodies primed to become potent immune weapons against cancer 3Environmental cleaning intervention reduces transmission of multidrug-resistant organisms in ICUs 2Plant biologists discover gene that switches on 'essence of male' 2